{
    "clinical_study": {
        "@rank": "19949", 
        "arm_group": [
            {
                "arm_group_label": "mildronate", 
                "arm_group_type": "Experimental", 
                "description": "infusion of mildronate"
            }, 
            {
                "arm_group_label": "cinepazide maleate", 
                "arm_group_type": "Active Comparator", 
                "description": "infusion of cinepazide maleate"
            }
        ], 
        "brief_summary": {
            "textblock": "Mildronate an inhibitor of carnitine-dependent metabolism, is considered an anti-ischemic\n      drug. This study aims to evaluate the efficacy and safety of mildronate injection in\n      treating acute ischemic stroke."
        }, 
        "brief_title": "Mildronate for Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, double-blind, multi-center clinical study was made on mildronate injection for\n      treating acute cerebral infarction. 113 cases in the experimental group were given with\n      mildronate injection, while 114 cases in the active-control group were given with cinepazide\n      maleate injection. In addition, both groups were given aspirin as basic treatments. Modified\n      Rankin Scale (mRS) score at 2 weeks and 3 months, National Institutes of Health Stroke Scale\n      (NIHSS) score and Barthel Index score at 2 weeks after treatment, vital signs and adverse\n      events were evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (i) had a clinical diagnosis of acute ischaemic stroke ,on the first episode within\n             the previous 7 days, and confirmed on CT or MRI brain imaging.(ii) were between 18 to\n             80 years of age (patients >= 70 years were not combined with any other poor physical\n             condition except ischaemic stroke )(iii)had a score of 5-22 on the National\n             Institutes of Health Stroke Scale (NIHSS).(iv)had a report that liver and kedney\n             function were less than 1.5 folds of normal value.\n\n        Exclusion Criteria:\n\n          -  (i) had other intracranial pathologies (e.g. cerebral hemorrhage, tumour, infection),\n             (ii) were pregnant or nursing ;(iii) had a neurological or psychiatric disease ;(iv)\n             had significant drug or alcohol misuse, (v)had been given thrombolytic therapy or\n             medication forbidden by study protocol; (vi)participated in a clinical trial in the\n             past 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "227", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831011", 
            "org_study_id": "xijing-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "mildronate", 
                "intervention_name": "mildronate injection", 
                "intervention_type": "Drug", 
                "other_name": "infusion of mildronate infusion of mildronate(500mg) once a day and for 14 da"
            }, 
            {
                "arm_group_label": "cinepazide maleate", 
                "intervention_name": "cinepazide maleate injection", 
                "intervention_type": "Drug", 
                "other_name": "infusion of plabcebo once a day and for 14 days"
            }, 
            {
                "arm_group_label": [
                    "mildronate", 
                    "cinepazide maleate"
                ], 
                "intervention_name": "aspirin", 
                "intervention_type": "Drug", 
                "other_name": "infusion of aspirin (100mg) once a day for days"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "3-(2,2,2-trimethylhydrazine)propionate", 
                "Maleic acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "randomized trial", 
            "acute ischemic stroke", 
            "mildronate"
        ], 
        "lastchanged_date": "April 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Xi an", 
                    "country": "China", 
                    "state": "Shanxi", 
                    "zip": "710032"
                }, 
                "name": "the Department of Neurology"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Mildronate for Acute Ischemic Stroke: a Randomized, Double-blind, Active-controlled Phase II Multicenter Trial", 
        "overall_official": [
            {
                "affiliation": "the Department of Neurology , Xijing Hospital", 
                "last_name": "Gang Zhao, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "the Department of Neurology , Xijing Hospital", 
                "last_name": "Guang Yun Zhang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "the Department of Neurology , Xijing Hospital", 
                "last_name": "Yi Zhu, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the modified Rankin scale", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "NIHSS scores", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "the Barthel index", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }
        ], 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}